Catalyst (CPRX) Soars 16.7%: Is Further Upside Left in the Stock?

Zacks01-09

Catalyst Pharmaceutical (CPRX) shares rallied 16.7% in the last trading session to close at $22.80. This move can be attributable to notable volume with a higher number of shares being traded than in ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2502046268?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-09 21:17","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2502046268","market":"us","top_or_hot":-1,"title":"Catalyst (CPRX) Soars 16.7%: Is Further Upside Left in the Stock?","media":"Zacks","content":"<div>\n<p>Catalyst Pharmaceutical (CPRX) shares rallied 16.7% in the last trading session to close at $22.80. This move can be attributable to notable volume with a higher number of shares being traded than in ...</p>\n\n<a href=\"https://finance.yahoo.com/news/catalyst-cprx-soars-16-7-131700002.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Catalyst (CPRX) Soars 16.7%: Is Further Upside Left in the Stock?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCatalyst (CPRX) Soars 16.7%: Is Further Upside Left in the Stock?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-09 21:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/catalyst-cprx-soars-16-7-131700002.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Catalyst Pharmaceutical (CPRX) shares rallied 16.7% in the last trading session to close at $22.80. This move can be attributable to notable volume with a higher number of shares being traded than in ...</p>\n\n<a href=\"https://finance.yahoo.com/news/catalyst-cprx-soars-16-7-131700002.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://finance.yahoo.com/news/catalyst-cprx-soars-16-7-131700002.html","article_id":"2502046268","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2502046268","pubTimestamp":1736428620,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Catalyst Pharmaceutical  shares rallied 16.7% in the last trading session to close at $22.80. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 11.7% loss over the past four weeks.This specialty drug company is expected to post quarterly earnings of $0.52 per share in its upcoming report, which represents a year-over-year change of -1.9%. Revenues are expected to be $132.71 million, up 20% from the year-ago quarter.Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.For Catalyst, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an ","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"Catalyst(CPRX)飙升16.7%：该股还有进一步上涨的空间吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CPRX":1,"IONS":0.9},"content_text":"Catalyst Pharmaceutical (CPRX) shares rallied 16.7% in the last trading session to close at $22.80. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 11.7% loss over the past four weeks.\nThe sudden rise in the stock price was observed after Catalyst, along with its licensor, SERB, announced that it has entered into a settlement agreement with Teva Pharmaceuticals regarding the Firdapse (amifampridine) patent litigation. The settlement agreement resolves the patent litigation brought by Catalyst and SERB on Teva for submitting an abbreviated new drug application to the FDA seeking marketing approval for a generic version of Firdapse 10 mg tablets before applicable patents expire.\nThis specialty drug company is expected to post quarterly earnings of $0.52 per share in its upcoming report, which represents a year-over-year change of -1.9%. Revenues are expected to be $132.71 million, up 20% from the year-ago quarter.\nEarnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.\nFor Catalyst, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on CPRX going forward to see if this recent jump can turn into more strength down the road.\nThe stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>\nCatalyst is part of the Zacks Medical - Drugs industry. Ionis Pharmaceuticals (IONS), another stock in the same industry, closed the last trading session 2.5% lower at $34.10. IONS has returned -8.6% in the past month.\nFor Ionis Pharmaceuticals , the consensus EPS estimate for the upcoming report has changed -0.4% over the past month to -$1.13. This represents a change of -1783.3% from what the company reported a year ago. Ionis Pharmaceuticals currently has a Zacks Rank of #3 (Hold).\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nCatalyst Pharmaceuticals, Inc. (CPRX) : Free Stock Analysis Report\nIonis Pharmaceuticals, Inc. (IONS) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.2","shortVersion":"4.30.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2502046268"}